Literature DB >> 20002658

No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients.

Florence Nicot1, Nassim Kamar, Bernard Mariamé, Lionel Rostaing, Christophe Pasquier, Jacques Izopet.   

Abstract

Persistence of hepatitis C virus (HCV) in patients who cleared HCV is still debated. Occult HCV infection is described as the presence of detectable HCV RNA in liver or peripheral blood mononuclear cells (PBMCs) of patients with undetectable plasma HCV-RNA by conventional PCR assays. We have assessed the persistence of HCV in 26 kidney-transplant patients, followed up for 10.5 years (range 2-16), after HCV elimination while on hemodialysis. If HCV really did persist, arising out of the loss of immune control caused by institution of the regimen of immunosuppressive drugs after kidney transplantation, HCV reactivation would have taken place. Their immunosuppression relied on calcineurin inhibitors (100%), and/or steroids (62%), and/or antimetabolites (94%). An induction therapy, given to 22 patients, relied on rabbit antithymocyte globulin (59%) or anti-IL2-receptor blockers (32%). All patients had undetectable HCV RNA as ascertained by several conventional tests. At the last follow-up, no residual HCV RNA was detected in the five liver biopsies, the 26 plasma, and in the 37 nonstimulated and 24 stimulated PBMCs tested with an ultrasensitive RT-PCR assay (detection limit, 2 IU/ml). No biochemical or virologic relapse was seen during follow-up. The absence of HCV relapse in formerly HCV-infected immunocompromised patients suggests the complete eradication of HCV after its elimination while on dialysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002658     DOI: 10.1111/j.1432-2277.2009.01025.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  19 in total

1.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

Review 2.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Authors:  Harrys A Torres; Marta Davila
Journal:  Nat Rev Clin Oncol       Date:  2012-01-24       Impact factor: 66.675

3.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

4.  Occult hepatitis C virus infection and its relevance in clinical practice.

Authors:  Tram Nq Pham; Tomasz I Michalak
Journal:  J Clin Exp Hepatol       Date:  2012-01-02

5.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

Review 6.  Hepatitis C virus infection in nephrology patients.

Authors:  Lionel Rostaing; Jacques Izopet; Nassim Kamar
Journal:  J Nephropathol       Date:  2013-07-01

Review 7.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

8.  Management of the kidney transplant patient with chronic hepatitis C infection.

Authors:  Ignatius Y S Tang; Natasha Walzer; Nidhi Aggarwal; Ivo Tzvetanov; Scott Cotler; Enrico Benedetti
Journal:  Int J Nephrol       Date:  2011-04-26

9.  Treatment of chronic hepatitis C virus infection in dialysis patients: an update.

Authors:  Hugo Weclawiak; Nassim Kamar; Abdellatif Ould-Mohamed; Isabelle Cardeau-Desangles; Jacques Izopet; Lionel Rostaing
Journal:  Hepat Res Treat       Date:  2010-09-20

10.  Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease.

Authors:  Laura De Marco; Paola Manzini; Morena Trevisan; Anna Gillio-Tos; Franca Danielle; Cinzia Balloco; Alessandra Pizzi; Eleonora De Filippo; Sergio D'Antico; Beatrice Violante; Adriano Valfrè; Franco Curti; Franco Merletti; Lorenzo Richiardi
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.